Evidence map›Paper›PMID 38805551›Full record

ArticlePLoS pathogens2024

Neoblast-like stem cells of Fasciola hepatica.

Paul McCusker, Nathan G Clarke, Erica Gardiner, Rebecca Armstrong, Erin M McCammick, Paul McVeigh, Emily Robb, Duncan Wells, Madelyn Nowak-Roddy, Abdullah Albaqami and 5 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. A practical miracidial motility assay for assessing Fasciola hepatica sensitivity to compounds in vitro.International journal for parasitology. Drugs and drug resistance · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. In vitro co-culture ofVirulence · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paul McCuskerUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.ORCID 0000-0003-0030-1594
Nathan G ClarkeUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Erica GardinerUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Rebecca ArmstrongUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Erin M McCammickUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Paul McVeighUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Emily RobbUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Duncan WellsUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Madelyn Nowak-RoddyUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Abdullah AlbaqamiUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Angela MousleyUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Jonathan A CoulterSchool of Pharmacy, Queen's University Belfast, Belfast, United Kingdom.
John HarringtonBoehringer Ingelheim Animal Health, Duluth, Georgia, United States of America.
Nikki J MarksUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.
Aaron G MauleUnderstanding Health & Disease, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom.

Funding

Biotechnology and Biological Sciences Research Council BB/T002727/1
6 · The paper itself

Abstract

The common liver fluke (Fasciola hepatica) causes the disease fasciolosis, which results in considerable losses within the global agri-food industry. There is a shortfall in the drugs that are effective against both the adult and juvenile life stages within the mammalian host, such that new drug targets are needed. Over the last decade the stem cells of parasitic flatworms have emerged as reservoirs of putative novel targets due to their role in development and homeostasis, including at host-parasite interfaces. Here, we investigate and characterise the proliferating cells that underpin development in F. hepatica. We provide evidence that these cells are capable of self-renewal, differentiation, and are sensitive to ionising radiation- all attributes of neoblasts in other flatworms. Changes in cell proliferation were also noted during the early stages of in vitro juvenile growth/development (around four to seven days post excystment), which coincided with a marked reduction in the nuclear area of proliferating cells. Furthermore, we generated transcriptomes from worms following irradiation-based ablation of neoblasts, identifying 124 significantly downregulated transcripts, including known stem cell markers such as fgfrA and plk1. Sixty-eight of these had homologues associated with neoblast-like cells in Schistosoma mansoni. Finally, RNA interference mediated knockdown of histone h2b (a marker of proliferating cells), ablated neoblast-like cells and impaired worm development in vitro. In summary, this work demonstrates that the proliferating cells of F. hepatica are equivalent to neoblasts of other flatworm species and demonstrate that they may serve as attractive targets for novel anthelmintics.

Indexed as

Cell ProliferationFasciola hepaticaFascioliasisStem CellsAnimalsCell Differentiation

Identifiers

PMID38805551
PMCPMC11161113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.